PTC Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $1,799.6 Mil.
Warning Sign:
If a company builds asset at 89.3% a year, faster than its revenue growth rate of 19% over the past 5 years, it means that the company may be getting less efficent.
During the past 12 months, PTC Therapeutics's average Total Assets Growth Rate was 7.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 9.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 89.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 78.70% per year.
During the past 11 years, PTC Therapeutics's highest 3-Year average Total Assets Growth Rate was 223.40%. The lowest was 4.60%. And the median was 67.60%.
Total Assets is connected with ROA %. PTC Therapeutics's annualizedROA % for the quarter that ended in Mar. 2022 was -27.12%. Total Assets is also linked to Revenue through Asset Turnover. PTC Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 was 0.08.
PTC Therapeutics Total Assets Historical Data
The historical data trend for PTC Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Total Assets
391.65
1,119.22
1,623.78
2,208.28
1,938.06
PTC Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Total Assets
2,111.94
2,058.67
2,007.33
1,938.06
1,799.59
PTC Therapeutics Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
PTC Therapeutics's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (NAS:PTCT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
PTC Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
PTC Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of PTC Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.99(3.14%) Volume: 437,430 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
